Skip to main content

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
  1. Home
  2. Healthcare professionals
  3. ACE Technology Guidances
  4. Drug Guidance
  5. Recombinant blood products for prophylaxis and management of haemophilia A and B
Drug guidance

Recombinant blood products for prophylaxis and management of haemophilia A and B

Condition

Blood and Immune System

19 December 2022

Published on 19 Dec 2022
Last Updated on 19 Dec 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended the following recombinant blood products for inclusion on the MOH Standard Drug List (SDL) for patients with haemophilia A (congenital factor VIII deficiency) and haemophilia B (congenital factor IX deficiency) in line with their registered indications when used as treatment and prophylaxis of bleeding episodes:

  • Octocog alfa (Advate) 250 IU, 500 IU, 1000 IU and 1500 IU powder and solvent for solution for injection

  • Rurioctocog alfa pegol (Adynovate) 250 IU, 500 IU, 1000 IU, 1500 IU, 2000 IU and 3000 IU powder and solvent for solution for injection

  • Nonacog alfa (BeneFIX) 250 IU, 500 IU, 1000 IU and 2000 IU powder and solvent for solution for injection.

Blood products that have not been recommended for subsidy due to unacceptable cost-effectiveness compared with subsidised alternatives are listed in the Annex.

The subsidy class and subsidy implementation dates (if applicable) for all blood products included in the review are provided in the Annex.

Recombinant blood products for prophylaxis and management of haemophilia A and B (19 December 2022) [PDF, 111 KB]

Back to top